Thus, improvement of insulin sensitivity and mitochondrial function was imperative to partially explain the therapeutic effects of TM5441, a novel agent targeting HFD-induced NAFLD. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.